These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 15989998

  • 1. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Allen ZA, Merrick GS, Butler WM, Wallner KE, Kurko B, Anderson RL, Murray BC, Galbreath RW.
    Int J Radiat Oncol Biol Phys; 2005 Jul 15; 62(4):981-7. PubMed ID: 15989998
    [Abstract] [Full Text] [Related]

  • 2. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2006 Jan 01; 64(1):136-43. PubMed ID: 16198062
    [Abstract] [Full Text] [Related]

  • 3. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1367-82. PubMed ID: 15275722
    [Abstract] [Full Text] [Related]

  • 4. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Murray B, Allen Z, Lief JH, Galbreath RW.
    Brachytherapy; 2004 Aug 01; 3(1):22-9. PubMed ID: 15110310
    [Abstract] [Full Text] [Related]

  • 5. Brachytherapy-related dysuria.
    Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Lief JH.
    BJU Int; 2005 Mar 01; 95(4):597-602. PubMed ID: 15705087
    [Abstract] [Full Text] [Related]

  • 6. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M, Studer G, Le L, McLean M, Yeung I, Pond G, Crook JM.
    Brachytherapy; 2007 Mar 01; 6(3):173-9. PubMed ID: 17681239
    [Abstract] [Full Text] [Related]

  • 7. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S, Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Adamovich E.
    BJU Int; 2006 Jan 01; 97(1):62-8. PubMed ID: 16336330
    [Abstract] [Full Text] [Related]

  • 8. The impact of radiation dose to the urethra on brachytherapy-related dysuria.
    Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Lief JH, Reed DJ.
    Brachytherapy; 2005 Jan 01; 4(1):45-50. PubMed ID: 15737906
    [Abstract] [Full Text] [Related]

  • 9. Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorably influence brachytherapy-related urinary morbidity.
    Beekman M, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW.
    Urology; 2005 Dec 01; 66(6):1266-70. PubMed ID: 16360455
    [Abstract] [Full Text] [Related]

  • 10. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL, Waterman FM, Kim H, Dicker AP.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1395-404. PubMed ID: 15275725
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Temporal resolution of urinary morbidity following prostate brachytherapy.
    Merrick GS, Butler WM, Lief JH, Dorsey AT.
    Int J Radiat Oncol Biol Phys; 2000 Apr 01; 47(1):121-8. PubMed ID: 10758313
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW.
    Urology; 2002 Oct 01; 60(4):650-5. PubMed ID: 12385927
    [Abstract] [Full Text] [Related]

  • 16. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J, Stock RG, Stone NN, Iannuzzi C, DeWyngaert JK.
    Radiat Oncol Investig; 1998 Oct 01; 6(3):135-41. PubMed ID: 9652912
    [Abstract] [Full Text] [Related]

  • 17. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J, Wallner K, Merrick G, True L, Cavanagh W, Sutlief S, Butler W.
    Brachytherapy; 2003 Oct 01; 2(2):108-13. PubMed ID: 15062149
    [Abstract] [Full Text] [Related]

  • 18. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ, Chen J, Stenger A, Matzkin H.
    Urology; 2007 Sep 01; 70(3):548-53. PubMed ID: 17905113
    [Abstract] [Full Text] [Related]

  • 19. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Katoh H, Noda SE, Ito K, Yamamoto T, Kashiwagi B, Nakano T.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):472-8. PubMed ID: 16168839
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.